LifeTech Scientific Corporation (HKG:1302)
Hong Kong · Delayed Price · Currency is HKD 1.690
-0.010 (-0.59%)
Feb 11, 2026, 1:29 PM HKT
LifeTech Scientific Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 1,328 | 1,304 | 1,267 | 1,097 | 925.33 | 642.3 | |
Revenue Growth (YoY) | 3.68% | 2.88% | 15.48% | 18.58% | 44.07% | -3.97% |
Cost of Revenue | 363.77 | 322.26 | 271.54 | 223.38 | 177.8 | 129.15 |
Gross Profit | 963.81 | 981.44 | 995.64 | 873.93 | 747.53 | 513.15 |
Selling, General & Admin | 650.9 | 504.2 | 414.59 | 347.7 | 291.18 | 320.48 |
Research & Development | 277.45 | 302.92 | 297.92 | 208.48 | 145.89 | 167.27 |
Other Operating Expenses | -35.02 | -37.1 | -46.04 | -51.24 | -47.03 | -47.12 |
Operating Expenses | 895.03 | 771.73 | 667.14 | 504.86 | 381.77 | 447.1 |
Operating Income | 68.77 | 209.71 | 328.5 | 369.07 | 365.77 | 66.05 |
Interest Expense | -1.14 | -1.89 | -0.72 | -0.63 | -2.61 | -25.69 |
Interest & Investment Income | 19.94 | 18.57 | 12.78 | 16.65 | 62.14 | 16.65 |
Earnings From Equity Investments | 5.99 | -0.66 | -1.96 | -1.77 | -0.87 | -2.82 |
Currency Exchange Gain (Loss) | 27.43 | 2.66 | 13.38 | 53.6 | -40.61 | -15.67 |
Other Non Operating Income (Expenses) | -1.33 | -1.33 | 1.51 | -1.99 | 0.24 | -1.35 |
EBT Excluding Unusual Items | 119.66 | 227.05 | 353.49 | 434.93 | 384.06 | 37.17 |
Gain (Loss) on Sale of Investments | 17.27 | 38.45 | 35.87 | -27.73 | -51.08 | 199.53 |
Gain (Loss) on Sale of Assets | -0.8 | -0.53 | -0.06 | -0.34 | 0.06 | 5.93 |
Asset Writedown | -65.97 | -65.97 | - | -21.31 | - | - |
Other Unusual Items | - | - | -213.72 | -7.5 | -0.11 | - |
Pretax Income | 70.15 | 199 | 175.58 | 378.05 | 332.93 | 242.62 |
Income Tax Expense | 45.7 | 30.5 | 68.09 | 59.31 | 49.57 | 35.58 |
Earnings From Continuing Operations | 24.45 | 168.49 | 107.49 | 318.74 | 283.36 | 207.04 |
Minority Interest in Earnings | 47.46 | 53.9 | 155.75 | 6.6 | 9.12 | 9.04 |
Net Income | 71.91 | 222.39 | 263.24 | 325.34 | 292.47 | 216.09 |
Net Income to Common | 71.91 | 222.39 | 263.24 | 325.34 | 292.47 | 216.09 |
Net Income Growth | -71.08% | -15.52% | -19.09% | 11.24% | 35.35% | 67.25% |
Shares Outstanding (Basic) | 4,341 | 4,379 | 4,356 | 4,233 | 4,309 | 4,338 |
Shares Outstanding (Diluted) | 4,344 | 4,394 | 4,446 | 4,405 | 4,563 | 4,389 |
Shares Change (YoY) | -1.76% | -1.16% | 0.92% | -3.45% | 3.95% | 5.97% |
EPS (Basic) | 0.02 | 0.05 | 0.06 | 0.08 | 0.07 | 0.05 |
EPS (Diluted) | 0.02 | 0.05 | 0.06 | 0.07 | 0.06 | 0.05 |
EPS Growth | -70.30% | -13.93% | -20.27% | 15.63% | 30.61% | 58.06% |
Free Cash Flow | 572.84 | 124.83 | 217.22 | 161.95 | 165.27 | 233.46 |
Free Cash Flow Per Share | 0.13 | 0.03 | 0.05 | 0.04 | 0.04 | 0.05 |
Gross Margin | 72.60% | 75.28% | 78.57% | 79.64% | 80.78% | 79.89% |
Operating Margin | 5.18% | 16.09% | 25.92% | 33.63% | 39.53% | 10.28% |
Profit Margin | 5.42% | 17.06% | 20.77% | 29.65% | 31.61% | 33.64% |
Free Cash Flow Margin | 43.15% | 9.57% | 17.14% | 14.76% | 17.86% | 36.35% |
EBITDA | 150.91 | 288.56 | 391.99 | 421.88 | 414.36 | 111.88 |
EBITDA Margin | 11.37% | 22.13% | 30.93% | 38.45% | 44.78% | 17.42% |
D&A For EBITDA | 82.13 | 78.85 | 63.5 | 52.81 | 48.59 | 45.83 |
EBIT | 68.77 | 209.71 | 328.5 | 369.07 | 365.77 | 66.05 |
EBIT Margin | 5.18% | 16.09% | 25.92% | 33.63% | 39.53% | 10.28% |
Effective Tax Rate | 65.15% | 15.33% | 38.78% | 15.69% | 14.89% | 14.67% |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.